0QZU.L - Vertex Pharmaceuticals Incorporated

LSE - LSE Prezzo differito. Valuta in USD.
324,33
+1,45 (+0,45%)
Alla chiusura: 05:54PM BST
Il grafico dei titoli non è supportato dal tuo browser attuale
Chiusura precedente322,88
Aperto0,00
Denaro0,00 x 0
Lettera0,00 x 0
Min-Max giorno0,00 - 0,00
Intervallo di 52 settimane
Volume1
Media Volume5.891
Capitalizzazione833,531M
Beta (5 anni mensile)0,49
Rapporto PE (ttm)0,34
EPS (ttm)9,48
Prossima data utili02 ago 2023 - 07 ago 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Catalyst Biosciences Reports Second Quarter 2022 Operating & Financial Results

    SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the “Company” or “we”) today announced its operating and financial results for the second quarter ended June 30, 2022. “We were very pleased to have completed the sale of our complement portfolio during the second quarter to Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) (“Vertex”) for $60.0 million in cash with up to $5.0 million of that amount due in May 2023. This transaction was the

  • GlobeNewswire

    Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease

    Verve to Receive $25 Million Upfront Payment and $35 Million Equity Investment, as Well as Potential Milestones and RoyaltiesBOSTON and CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Verve Therapeutics, Inc. (Nasdaq: VERV) today announced an exclusive, four-year global research collaboration focused on discovering and developing an in vivo gene editing program for a single undisclosed liver disease. Under the terms of the collaboration,